Literature DB >> 17016145

Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.

Masahiro Serikawa1, Tamito Sasaki, Yoshifumi Fujimoto, Kenichi Kuwahara, Kazuaki Chayama.   

Abstract

GOALS: The aim of this study was to examine and clarify the preoperative markers that are useful for differentiating between benign and malignant lesions of intraductal papillary-mucinous neoplasms (IPMN) of the pancreas, grouped according to morphologic classification.
BACKGROUND: There are various stages of pathology in IPMN, ranging from benign to malignant lesions. Although the determination of appropriate treatment guidelines to deal with IPMN is a critical issue, no such guidelines have been established. PATIENTS AND METHODS: One hundred twenty cases of IPMN were classified morphologically into either main or branch duct types. We compared the morphologic classification with histopathologic diagnosis using indicators of malignancy detected by imaging such as main duct diameter, the number and diameter of cysts, and the presence or absence of mural nodules. We also examined the usefulness of pancreatic juice cytology and measurement of telomerase activity as indicators of malignancy. Finally, we performed a survival analysis on the basis of morphologic classification to determine prognosis of IPMN.
RESULTS: Whereas a high incidence (64%) of malignant lesions was seen in main duct type IPMN, benign lesions were dominant (80.5%) in branch duct type IPMN. Survival analysis showed that the prognosis was significantly worse in main duct type than in branch duct type IPMN. The lesions were aggravated in all patients with main duct type who did not undergo resection, resulting in death due to progression of the pancreatic lesion. The incidence of mural nodules was a useful indicator in main duct type, whereas main duct diameter and incidence of mural nodules were useful indicators in branch duct type. Although pancreatic juice cytology showed a high accuracy rate with low sensitivity for determining malignancy, measurement of telomerase activity in this juice was very effective for differentiating between benign and malignant lesions.
CONCLUSIONS: The incidence of malignant lesions was extremely high in main duct type IPMN, indicating that surgery is required in all these patients. However, to determine whether surgery is indicated in branch duct type IPMN it is necessary to obtain an appropriate image diagnosis focusing on main duct diameter and mural nodules and also to carry out cytology and measurement of telomerase activity in samples of pancreatic juice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016145     DOI: 10.1097/01.mcg.0000225609.63975.6f

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  27 in total

Review 1.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

2.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms.

Authors:  Paula Ghaneh; John Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 3.  [Branch duct intraductal papillary mucinous neoplasm - surgical approach].

Authors:  J Kaiser; M W Büchler; T Hackert
Journal:  Chirurg       Date:  2017-11       Impact factor: 0.955

4.  Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct.

Authors:  Mee Joo Kang; Jin-Young Jang; Selyeong Lee; Taesung Park; Seung Yeoun Lee; Sun-Whe Kim
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

5.  Natural history of intraductal papillary mucinous neoplasia: How much do we really know?

Authors:  Chad G Ball; Thomas J Howard
Journal:  World J Gastrointest Surg       Date:  2010-10-27

6.  Acute pancreatitis: pancreas divisum with ventral duct intraductal papillary mucinous neoplasms.

Authors:  Krishna C Gurram; Agata Czapla; Shyam Thakkar
Journal:  BMJ Case Rep       Date:  2014-10-07

7.  Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience.

Authors:  Marco Niedergethmann; Robert Grützmann; Ralf Hildenbrand; Dag Dittert; Niloufar Aramin; Melanie Franz; Frank Dobrowolski; Stefan Post; Hans-Detlev Saeger
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

Review 8.  [Differentiated therapy for intraductal papillary mucinous neoplasms].

Authors:  M N Wente; B M Schmied; J Schmidt; M W Büchler
Journal:  Chirurg       Date:  2009-01       Impact factor: 0.955

Review 9.  Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yoshiyuki Nakajima; Takatsugu Yamada; Masayuki Sho
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

Review 10.  Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.

Authors:  Michael B Farnell
Journal:  J Gastrointest Surg       Date:  2007-10-30       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.